Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Prospective Randomised Comparison of Imatinib (STI571, Glivec/Gleevec) 400mg Daily Versus Dasatinib 100mg in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia

NCT01460693 is registered in ClinicalTrials.gov with Newcastle University as lead sponsor.

NCT NCT01460693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01460693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Prospective Randomised Comparison of Imatinib (STI571, Glivec/Gleevec) 400mg Daily Versus Dasatinib 100mg in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia
Lead sponsor
Newcastle University
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2008
Completion date
March 7, 2018
Enrollment
814 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myeloid leukemia, chronic, chronic phase